Abstract
There is ongoing controversy regarding the association between loop diuretics (LD), especially in high doses, and adverse clinical outcomes in outpatients with heart failure (HF). We performed a systematic review of the evidence for LD in outpatients with HF. We searched MEDLINE, EMBASE, and Cochrane Clinical Trial Collection to identify controlled studies, evaluating the association between LD and morbidity and mortality in patients with HF. The primary endpoint was all-cause mortality and secondary endpoint HF hospitalizations. Quantitative analysis was performed by generating forest plots and pooling adjusted risk estimates across studies using random effects models. Between-study heterogeneity was assessed through Q and I2 statistics. Twenty-four studies with a total of 96,959 patients were included. No randomized studies were identified. Use of LD was associated with increased all-cause mortality compared with non-use (pooled adjusted risk estimates, 1.18; P = 0.001) and increased HF hospitalization rates (pooled adjusted risk estimates, 1.81; P < 0.001). These associations remained significant after excluding studies that included HF patients at discharge from hospital (pooled adjusted risk estimates, 1.31 and 1.89, respectively; P < 0.001 for both). High-dose LD (median dose 80 mg) were also associated with increased all-cause mortality (pooled adjusted risk estimates, 1.99; P < 0.001) compared with low-dose LD. Again, this association remained significant after excluding studies that included HF patients at discharge from hospital (pooled adjusted risk estimates, 1.33; P < 0.001). Existing evidence indicates that LD, especially in high doses, are associated with increased all-cause mortality and HF hospitalization rates. For this reason, prospective, randomized studies are warranted to clarify whether these associations indicate causality or are merely an epiphenomenon due to disease severity. Systematic review registration: PROSPERO database registration number CRD42020153239. Date of registration: 28 April 2020.
Similar content being viewed by others
Data availability
Not provided.
References
Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010) HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16(6):e1–e194
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975
Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, Emerman CL, ADHERE Scientific Advisory Committee and Investigators (2009) Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 113(1):12–19
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18(6):613–625
Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–1675
Zannad F, JJ MM, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21
Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ (2012) Diuretics for heart failure. Cochrane Database Syst Rev (2):CD003838
Kapelios CJ, Malliaras K, Nanas JN (2016) Dosing of loop diuretics in chronic heart failure: it’s time for evidence. Eur J Heart Fail 18(10):1298
Kapelios CJ, Malliaras K, Kaldara E, Vakrou S, Nanas JN (2018) Loop diuretics for chronic heart failure: a foe in disguise of a friend? Eur Heart J Cardiovasc Pharmacother 4(1):54–63
Kapelios CJ, Kaldara E, Ntalianis A, Sousonis V, Repasos E, Sfakianaki T, Vakrou S, Pantsios C, Nanas JN, Terrovitis JV (2015) High furosemide dose has detrimental effects on survival of patients with stable heart failure. Hell J Cardiol 56:154–159
Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764
Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160:264–271.e1
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
Available online at: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=153239. Last accessed May 6, 2020
Simonavičius J, Knackstedt C, Brunner-La Rocca HP (2019) Loop diuretics in chronic heart failure: how to manage congestion? Heart Fail Rev 24(1):17–30
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155
Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JPT (2016) ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919
Higgins JPT, Green S, eds (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org
Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M, PRAISE Investigators (2002) Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144(1):31–38
Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E, Studies of Left Ventricular Dysfunction (2003) Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 42(4):705–708
Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27(12):1431–1439
Domanski M, Tian X, Haigney M, Pitt B (2006) Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 12(5):327–332
Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, Baughman KL, Stevenson LW, Givertz MM (2008) The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 14(5):388–393
Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE (2011) Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58:375–382
Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H, JCARE-CARD Investigators (2012) Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 76(8):1920–1927
Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, Genta FT, Cicoira M, Tavazzi L, Temporelli PL (2013) Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract 67(7):656–664
Vidula H, Butler J, Subacius H, Fonarow G, Nodari S, Konstam M, Gheorghiade M (2013) Diuretic dose and outcomes among hospitalized heart failure patients: insights from the EVEREST trial. J Am Coll Cardiol 61:E690 Abstract
Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 18(3):328–336
Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H, CHART-2 Investigators (2016) Prognostic impact of loop diuretics in patients with chronic heart failure—effects of addition of renin-angiotensin-aldosterone system inhibitors and β-blockers. Circ J 80(6):1396–1403
Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, Kazmi S, Clark AL (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther 30(6):599–609
Sargento L, Simões AV, Longo S, Lousada N, Reis RP (2017) Furosemide prescription during the dry state is a predictor of long-term survival of stable, optimally medicated patients with systolic heart Failure.J. Cardiovasc Pharmacol Ther 22(3):256–263
Galochkin S, Padaryan S, Babaeva L, Shavarova E, Villevalde S, Kobalava Z (2017) Predictors of six-month mortality after discharge in patients hospitalized with decompensated chronic heart failure. Eur J Heart Fail 19(Suppl. S1):486 Abstract
Costa J, Simone L, Héroguelle V, Nazeyrollas P, Metz D (2017) Furosemide doses and long-term mortality after discharge from heart failure episode: the FACT–HF study. Arch Cardiovasc Dis Suppl 9:39 Abstract
Laszczyńska O, Severo M, Friões F, Lourenço P, Silva S, Bettencourt P, Lunet N, Azevedo A (2017) Prognostic effect of the dose of loop diuretic over 5 years in chronic heart failure. J Card Fail 23(8):589–593
Gonzalez-Loyola F, Abellana R, Verdú-Rotellar JM, Bustamante Rangel A, Clua-Espuny JL, Muñoz MA (2018) Mortality in heart failure with atrial fibrillation: role of digoxin and diuretics. Eur J Clin Investig 48(11):e13014
Kapelios C, Laroche C, Crespo-Leiro MG, Piepoli M, Coats A, Anker SD, Filippatos G, Maggioni A, Seferovic P, Rosano G, Mebazaa A, Lainscak M, Hoes A, Ruschitzka F, Lund LH (2018) High-dose loop diuretics are associated with adverse clinical outcomes in outpatients with chronic heart failure and mid-range and preserved ejection fraction: observations from the ESC heart failure. Eur J Heart Fail 20(Suppl. S1):7 Abstract
Okabe T, Yakushiji T, Kido T, Oyama Y, Igawa W, Ono M, Ebara S, Yamashita K, Yamamoto MH, Saito S, Amemiya K, Isomura N, Ochiai M (2018) The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail 5(1):87–94
Parén P, Dahlström U, Edner M, Lappas G, Rosengren A, Schaufelberger M (2018) Association of diuretic treatment at hospital discharge in patients with heart failure with all-cause short- and long-term mortality: a propensity score-matched analysis from SwedeHF. Int J Cardiol 257:118–124
Fröhlich H, Rosenfeld N, Täger T, Goode K, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L, Grundtvig M (2019) Epidemiology and long-term outcome in outpatients with chronic heart failure in northwestern Europe. Heart 105(16):1252–1259
Kapelios CJ, Kaldara E, Ntalianis A, Nana E, Pantsios C, Repasos E, Margari Z, Sousonis V, Malliaras K, Nanas JN (2014) Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: a randomized study. Int J Cardiol 177(2):690–692
McKie PM, Schirger JA, Benike SL, Harstad LK, Chen HH (2014) The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure. JACC Heart Fail 2(6):675–677
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure—activation of the neurohumoral axis. Ann Intern Med 103:1–6
Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P (1987) Untreated heart-failure—clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57:17–22
Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ (1999) Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100:1311–1315
Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35(7):455–469
Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Díaz-Molina B, Filippatos G, Lainscak M, Maggioni AP, McDonagh T, Mebazaa A, Metra M, Moura B, Mullens W, Piepoli MF, Rosano GMC, Ruschitzka F, Seferovic PM, Lund LH, On behalf of the Heart Failure Long Term Registry Investigators Group (2020) Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC EORP heart failure long-term registry. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1796
Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simões MV, Silvestre OM, Ribeiro ALP, Moura LZ, Beck-da-Silva L, Prado D, Sant'Anna RT, Bridi LH, Zimerman A, Raupp da Rosa P, Biolo A (2019) Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J 40(44):3605–3612
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 28 kb).
Rights and permissions
About this article
Cite this article
Kapelios, C.J., Bonou, Μ., Malliaras, K. et al. Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients. Heart Fail Rev 27, 147–161 (2022). https://doi.org/10.1007/s10741-020-09995-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-020-09995-z